Demo
GEHC Nasdaq· GE HealthCare Technologies Inc
FundamentalsNews digest Peer analysis
Login
GEHC Nasdaq· GE HealthCare Technologies Inc
Earnings report Q4 2023

GEHC Reports Strong Revenue Growth in Latest Quarter

Segments of revenue

GEHC's revenue in the latest quarter was $19.55 billion, representing a 7% increase compared to the same quarter last year. The company's revenue growth was driven by strong performances across all four reportable segments. The Imaging segment generated $10.58 billion in revenue, a 6% increase year-over-year. The Ultrasound segment saw a 1% increase in revenue, reaching $3.46 billion. The Patient Care Solutions (PCS) segment experienced significant growth with revenue of $3.14 billion, an 8% increase. The Pharmaceutical Diagnostics (PDx) segment showed the highest growth rate, with revenue of $2.31 billion, an impressive 18% increase.

Strengths

GEHC demonstrated strong revenue growth in the latest quarter, driven by solid performances across all segments. The company's focus on commercial and marketing investments, as well as increased R&D investments, contributed to its revenue growth. The Imaging segment, which is the largest revenue contributor, showed steady growth. Additionally, the PCS segment's strong performance indicates a growing demand for patient care solutions. The PDx segment's exceptional growth can be attributed to increased demand for pharmaceutical diagnostics.

Challenges

Despite the overall revenue growth, GEHC faced some challenges in the latest quarter. The company experienced a decrease in net income attributable to GEHC, which declined by $348 million and 240 basis points. This decrease was primarily due to a decrease in operating income, increased interest and other financial charges, and non-operating benefit income related to pension plans transferred to GEHC as part of the Spin-Off. These factors impacted the company's profitability and net income margin.

Noteworthy

It is worth mentioning that GEHC's revenue growth of 7% exceeded the industry average, indicating the company's strong market position. The PDx segment's exceptional growth of 18% highlights the success of GEHC's pharmaceutical diagnostics offerings. Additionally, the increase in R&D investments demonstrates the company's commitment to innovation and product development.

Summary

GEHC delivered a strong performance in the latest quarter, with a 7% increase in revenue. The company's revenue growth was driven by solid performances across all segments, particularly in the Imaging, PCS, and PDx segments. Despite facing challenges in terms of decreased net income and increased financial charges, GEHC's revenue growth exceeded industry expectations. The company's focus on commercial and marketing investments, as well as increased R&D investments, contributed to its strong performance. Overall, GEHC's latest quarter results indicate a positive outlook for the company's future growth and market position.

Source documents

Form 10-K  filed on Feb 06, 2024
5 pages scanned

Reference data

Company financials Q4 revenue 5.21B
Analyst estimates Q4 EPS beat by 9.82%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.